Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

After hours: November 29 at 4:53 PM EST Loading Chart for SRPT ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an ...

By empowering local organizations to help break down barriers to accessibility, the Government of Canada is helping to ensure that more Canadians with disabilities can access the services and programs ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...

Piper Sandler、Chardan Capital Markets和花旗都对这一发展做出了反应。Piper Sandler将Arrowhead的12个月目标价从之前的$62下调至$45，同时维持超配评级。Chardan Capital Markets维持对Arrowhead的买入评级和$60.00的股票目标价。花旗则略微下调目标价，从$27.00降至$26.00，同时保持对该股票的中性立场 ...

In recent weeks, global markets have experienced a broad-based rally with smaller-cap indexes outperforming large-caps, driven by strong labor market data and positive sentiment from economic ...